Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering our community to take control of diabetes.
Comprehend the needs of people affected by diabetes.
Act in the best interest of our community.
Use technology to revolutionize diabetes care.
Inspire confidence within our community and in one another.
The Dexcom G5 Mobile CGM System became the first and only fully mobile CGM system to allow adults and children as young as two years old the convenience of monitoring their glucose levels from a compatible smart device. It also gave patients the option to safely share their glucose data with others.
The Share feature for the G4 PLATINUM CGM System gave patients the option to share their glucose information with up to five followers through Dexcom Share and Follower apps on their smart devices via a secure wireless connection.
The G4 PLATINUM's overall accuracy and ease of use set a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available at the time.
The SEVEN® PLUS System launched as Dexcom’s third generation device designed to help people with diabetes better manage their glucose levels.
Study data presented by the Juvenile Diabetes Research Foundation (JDRF) at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) showed the use of CGM to be effective in the management of type 1 diabetes.
Dexcom launched the SEVEN® CGM System, the first CMG system approved for up to seven days of continual use.
Dexcom launched the first generation continuous glucose monitor designed to help people with diabetes more conveniently and effectively manage their blood sugar levels.
The initial public offering (IPO) for Dexcom was announced on the NASDAQ Stock Market under DXCM.
Three generations of Dexcom’s long-term implantable sensors were developed and studied in humans.
Dexcom was founded based on the groundbreaking research of Dr. Stuart J. Updike and George P. Hicks in 1967—implantable, long-performing glucose sensors that the body would not reject. Dr. Updike joined Dexcom that year to continue CGM innovation.